Bioventus Inc.BVSNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank75
3Y CAGR-13.0%
5Y CAGR+9.1%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-13.0%/yr
vs +24.2%/yr prior
5Y CAGR
+9.1%/yr
Recent deceleration
Acceleration
-37.2pp
Decelerating
Percentile
P75
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$328.40M-17.9%
2024$400.20M-2.4%
2023$409.92M-17.7%
2022$498.31M+71.5%
2021$290.64M+36.9%
2020$212.28M-2.6%
2019$218.01M+4.1%
2018$209.50M+21.1%
2017$172.94M+2.8%
2016$168.22M-